HEPION PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $670.00K.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $2.09M.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $868.82K.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2022-03-31 was $5.01K, a 99.99% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2024 was $868.82K, a 2171942.50% increase from fiscal 2023.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2023 was $40.00, a 99.20% decline from fiscal 2022.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2022 was $5.01K, a 99.99% decline from fiscal 2021.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2021 was $82.15M, a 91.65% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $670.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $2.09M 10-Q · filed 2025-08-14 | |
| 2024-12-31 | $868.82K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $868.82K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $40.00 10-K · filed 2025-04-08 | |
| 2022-12-31 | $5.01K 10-K · filed 2024-04-16 | |
| 2022-03-31 | $5.01K 10-Q · filed 2023-11-20 | |
| 2021-12-31 | $82.15M 10-K · filed 2023-04-10 | |
| 2021-03-31 | $82.15M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $42.87M 10-K · filed 2022-04-08 | |
| 2020-06-30 | $4.46M 10-Q · filed 2021-11-15 | $13.09M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-03-31 | $6.79M 10-Q · filed 2021-11-15 | $14.47M derived: sum of 4 quarters · filed 2021-11-15 |
| 2019-12-31 | $7.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $7.68M 10-K · filed 2021-03-31 |
| 2019-09-30 | -$5.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $315.50K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $5.84M 10-Q · filed 2020-11-16 | $6.09M derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-03-31 | $150.00K 10-Q · filed 2019-05-15 | $315.58K derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | $91.84K derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-14 | $1.99M 10-K · filed 2020-05-14 |
| 2018-09-30 | $84.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $1.99M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $73.66K 10-Q · filed 2019-08-14 | $3.31M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-03-31 | $1.82M 10-Q · filed 2019-11-14 | $14.33M derived: sum of 4 quarters · filed 2019-11-14 |
| 2017-12-31 | $92.71K derived: 10-K 6 month − 10-Q 3 month · filed 2019-03-14 | $13.30M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-09-30 | $1.32M 10-Q · filed 2017-11-14 | $25.92M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | $11.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $24.66M 10-K · filed 2019-03-14 |
| 2017-03-31 | $796.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-04-12 | $19.90M derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-12-31 | $12.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-14 | $19.10M derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-09-30 | $56.16K 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $6.34M derived: 10-KT 12 month − 10-Q 9 month · filed 2018-03-26 | $19.86M 10-KT · filed 2018-03-26 |
| 2016-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-13 | |
| 2015-03-31 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |